Short-term pulse pressure variability: a novel prognostic marker and therapeutic target in patients with vascular Ehlers-Danlos syndrome? Preliminary results from a pilot study

• Published in: Hypertension research Vol. 48; no. 4; pp. 1529 - 1541
• Main Authors: Buso, Giacomo, Gatta, Roberto, Corvini, Federica, Laera, Nicola, Agabiti-Rosei, Claudia, Paini, Anna, Bulgari, Giuseppe, Petroboni, Beatrice, Bertacchini, Fabio, Aggiusti, Carlo, Stassaldi, Deborah, Capellini, Sara, Salvetti, Massimo, De Ciuceis, Carolina, Ritelli, Marco, Venturini, Marina, Colombi, Marina, Muiesan, Maria Lorenza
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.04.2025; Nature Publishing Group
• Subjects: Adult; Antihypertensive Agents - therapeutic use; Blood pressure; Blood Pressure - drug effects; Blood Pressure - physiology; Blood Pressure Monitoring, Ambulatory; Celiprolol - pharmacology; Celiprolol - therapeutic use; Clinical medicine; Connective tissue diseases; Drug dosages; Ehlers-Danlos Syndrome - drug therapy; Ehlers-Danlos Syndrome - physiopathology; Ehlers-Danlos Syndrome, Type IV; Female; Fistula; Geriatrics/Gerontology; Health Promotion and Disease Prevention; Humans; Hypertension; Hypertension - drug therapy; Hypertension - physiopathology; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Obstetrics/Perinatology/Midwifery; Pilot Projects; Prognosis; Public Health; Retrospective Studies; Veins & arteries; Blood pressure variability; Celiprolol; Vascular Ehlers-Danlos syndrome; Ambulatory blood pressure monitoring
• ISSN: 0916-9636; 1348-4214; 1348-4214
• DOI: 10.1038/s41440-025-02135-w

Vascular Ehlers-Danlos syndrome (vEDS) is an inherited connective tissue disorder characterized by arterial fragility. Celiprolol is a β1-adrenoceptor antagonist with partial β2 agonist activity capable of reducing rates of vascular events in this setting, though the underlying mechanisms have yet to be elucidated. In particular, no conclusive evidence exists on its impact on blood pressure (BP) parameters in patients with vEDS. Accordingly, the aim of our study was to perform a comprehensive assessment of BP profile in a cohort of patients with vEDS receiving celiprolol titrated to the maximum tolerated dose. Consecutive outpatients with molecularly confirmed vEDS undergoing office BP measurement and 24-h ambulatory BP monitoring (ABPM) were retrospectively evaluated. Using 24-h systolic BP, diastolic BP, mean BP, and pulse pressure (PP) (mmHg) values, indices of short-term BP variability were calculated. A generalized linear regression model was applied to analyze the correlation between initial values of BP parameters and their variation with celiprolol therapy. Overall, 20 subjects were included (12 females). Eight patients (40%) had 24-h ABPM values consistent with hypertension. Five subjects (25%) defined hypertensives at 24-h ABPM had optimal BP control at office BP measurement, suggesting a “masked” hypertension. A significant correlation was found between initial values of indices of short-term PP variability and their change with celiprolol therapy, with a particularly high Pearson’s index for PP coefficient of variation ( r  = −0.926; p  < 0.001). In patients with vEDS, 24-h ABPM is confirmed a reliable tool in identifying hypertension phenotypes. Treatment with celiprolol may reduce PP variability proportionally to its initial magnitude. Dedicated studies on larger cohorts should evaluate whether short-term PP variability is a reliable prognostic marker and therapeutic target in this clinical setting. In our study, treatment with celiprolol seemed to reduce short-term PP variability proportionally to its initial magnitude in patients with vEDS. Furthermore, two out of four patients experiencing vascular events during the study period displayed the highest short-term PP variability values recorded in the entire cohort. Further research should evaluate whether such parameters are reliable prognostic markers and therapeutic targets in this clinical setting. ABPM ambulatory blood pressure monitoring, ARV average real variability, BP blood pressure, CV coefficient of variation, DBP diastolic blood pressure, PP pulse pressure, SBP systolic blood pressure, SD standard deviation, TRI time-rate index, vEDS vascular Ehlers-Danlos syndrome. In our study, treatment with celiprolol seemed to reduce short-term PP variability proportionally to its initial magnitude in patients with vEDS. Furthermore, two out of four patients experiencing vascular events during the study period displayed the highest short-term PP variability values recorded in the entire cohort. Further research should evaluate whether such parameters are reliable prognostic markers and therapeutic targets in this clinical setting. ABPM ambulatory blood pressure monitoring, ARV average real variability, BP blood pressure, CV coefficient of variation, DBP diastolic blood pressure, PP pulse pressure, SBP systolic blood pressure, SD standard deviation, TRI time-rate index, vEDS vascular Ehlers-Danlos syndrome.